Anticoagulants in coronary artery disease.
Anticoagulant therapy for acute coronary syndromes is becoming more complex as newer agents are added to unfractionated heparin and warfarin. The anticoagulants used in current clinical practice are low molecular weight heparins, direct thrombin inhibitors, and heparinoids. Properties of and recent clinical trial data regarding these newer anticoagulants are reviewed in reference to current American College of Cardiology/American Heart Association guidelines.
Lee
L Veronica
LV
Division of Cardiology, Yale University School of Medicine, 789 Howard Avenue, FMP3, New Haven, CT 06437, USA. lveronica.lee@yale.edu
D054058:Acute Coronary Syndrome / Q000188:drug therapy*; D000789:Angina, Unstable / Q000188:drug therapy*; D000925:Anticoagulants / Q000494:pharmacology / Q000627:therapeutic use*; D000991:Antithrombins / Q000627:therapeutic use; D004562:Electrocardiography; D006493:Heparin / Q000627:therapeutic use; D006495:Heparin, Low-Molecular-Weight / Q000627:therapeutic use; D006496:Heparinoids / Q000627:therapeutic use; D006801:Humans; D009203:Myocardial Infarction / Q000188:drug therapy* / Q000503:physiopathology; D015912:Thrombolytic Therapy; D013927:Thrombosis / Q000517:prevention & control
D000925:Anticoagulants; D000991:Antithrombins; D006495:Heparin, Low-Molecular-Weight; D006496:Heparinoids; D006493:Heparin